A German study protocol describes a web-based survey of 256 medical cannabis patients across three federal states, using validated questionnaires to assess symptoms before and during cannabinoid therapy.
Read this if you are interested in medical cannabis research methodology or how Germany is building its evidence base for cannabinoid therapy.
256 patientsRepresentative sample recruited via physician cluster sampling in three German states
What the researchers found
This study protocol outlines an exploratory mixed-methods survey of medical cannabis patients in Germany, where broader prescribing was allowed since 2017. The design addresses key challenges: stigmatization limiting patient willingness to participate, low prevalence making recruitment difficult, and the need for representative sampling. Using cluster sampling via statutory health insurance physicians, they recruited 256 patients. Validated questionnaires cover pain, spasticity, anorexia, MS, nausea, depression, and ADHD symptoms both currently and retrospectively before treatment.
Why it matters
Germany's medical cannabis system is growing but lacks systematic patient outcome data. This protocol demonstrates how to overcome methodological challenges in studying a stigmatized, hard-to-reach treatment population.
The numbers in context
- 256 patients enrolled through June 2022
- 3 German federal states
- Prescribing allowed since 2017
- Conditions assessed: pain, spasticity, anorexia, MS, nausea, depression, ADHD
- Web-based, anonymous, cross-sectional design
How the study worked
Representative, anonymous, cross-sectional web-based survey. Cluster sampling via statutory health insurance physicians. Validated symptom-specific questionnaires for current and pre-therapy conditions. Mixed methods with prior qualitative interviews informing survey design.
Who was studied
256 outpatients prescribed medical cannabinoids in three German federal states
What this study cannot tell us
Study protocol, not results. Cross-sectional design cannot establish causation. Retrospective pre-therapy assessment subject to recall bias. Web-based format may exclude less technology-literate patients.
How to read the evidence
Study protocol publication. Describes methodology but presents no outcome data.
When this study was published
Published in 2023. Reflects Germany's approach to building medical cannabis evidence since 2017 legalization.
The bigger picture
As medical cannabis programs expand globally, developing standardized methods for capturing patient experiences and outcomes is essential. This German protocol could serve as a model for other jurisdictions.
Questions still open
- What will the results show about cannabinoid therapy effectiveness across conditions?
- Can this methodology be replicated in other European countries with medical cannabis programs?
- Will the retrospective symptom assessment accurately capture pre-treatment status?
Read the original research
Patient Experiences With Prescription Cannabinoids in Germany: Protocol for a Mixed Methods, Exploratory, and Anonymous Web-Based Survey.
JMIR research protocols, 12, e38814
Citation
Fischer, Jan Moritz; Kandil, Farid-Ihab; Karst, Matthias; Zager, Laura Sophie; Jeitler, Michael; Kugler, Felix; Fitzner, Franziska; Michalsen, Andreas; Kessler, Christian S. (2023). Patient Experiences With Prescription Cannabinoids in Germany: Protocol for a Mixed Methods, Exploratory, and Anonymous Web-Based Survey.. JMIR research protocols, 12, e38814. https://doi.org/10.2196/38814